News + Stories

News + Stories

Under the Microscope: Sami Barmada, M.D., Ph.D. on Biomarkers and Therapeutic Targets for ALS and FTD

Under the Microscope: Sami Barmada, M.D., Ph.D. on Biomarkers and Therapeutic Targets for ALS and FTD

Finding The Light Amidst ALS: Sunny Brous’ Story

Finding The Light Amidst ALS: Sunny Brous’ Story

The Power of Community + ALS: Bryan Rosica’s Story

The Power of Community + ALS: Bryan Rosica’s Story

To Dad, With Love: One Daughter’s Story of a Father’s ALS Journey

To Dad, With Love: One Daughter’s Story of a Father’s ALS Journey

From an Arm Twitch To ALS Advocacy

From an Arm Twitch To ALS Advocacy

Target ALS Announces “Becca,” a One-Night Only Streaming Concert Fundraiser Featuring Broadway’s Best-Known Stars, in Memory of Rebecca Luker

Target ALS Announces “Becca,” a One-Night Only Streaming Concert Fundraiser Featuring Broadway’s Best-Known Stars, in Memory of Rebecca Luker

Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS Biomarkers

Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS Biomarkers

Target ALS Launches The First-Ever Comprehensive Research Initiative to Discover Urgently Needed ALS Biomarkers

Target ALS Launches The First-Ever Comprehensive Research Initiative to Discover Urgently Needed ALS Biomarkers

Research Funding Decisions Made Fair; Independent Review is Key

Research Funding Decisions Made Fair; Independent Review is Key

We Salute You: Tom’s Life Was Defined By Much, But Not By ALS

We Salute You: Tom’s Life Was Defined By Much, But Not By ALS

Living Life to the Fullest: Eric’s Story of Giving ALS a Run for Its Money

Living Life to the Fullest: Eric’s Story of Giving ALS a Run for Its Money

Tripper’s Five Tips to Take on “The Toughest Challenge” in Support of ALS Research

Tripper’s Five Tips to Take on “The Toughest Challenge” in Support of ALS Research

ALS Charity Gets Creative During COVID-19 By Taking On ‘The Toughest Challenge’

ALS Charity Gets Creative During COVID-19 By Taking On ‘The Toughest Challenge’

Under The Microscope: The Role of Genomics in ALS Research

Under The Microscope: The Role of Genomics in ALS Research

Meet The Toughest Challenge For The Hardest Fight / Join Us to Make a Difference

Meet The Toughest Challenge For The Hardest Fight / Join Us to Make a Difference

5 Answers About ALS From Our CEO

5 Answers About ALS From Our CEO

Our ROI: Impact to Date of the Target ALS Innovation Ecosystem

Our ROI: Impact to Date of the Target ALS Innovation Ecosystem

‘The Unexpected Artist’: Guest Post by Ron Hoffman, Compassionate Care ALS Founder

‘The Unexpected Artist’: Guest Post by Ron Hoffman, Compassionate Care ALS Founder

‘Never Say Invisible’: One Family’s Perspective on Living with ALS

‘Never Say Invisible’: One Family’s Perspective on Living with ALS

UNDER THE MICROSCOPE: Why TDP-43 Matters So Much in ALS Research

UNDER THE MICROSCOPE: Why TDP-43 Matters So Much in ALS Research

Under the Microscope: Sophie Parmentier-Batteur on Interrogating a Protein Compound for Possible Therapeutic Approaches to ALS and FTD

Under the Microscope: Sophie Parmentier-Batteur on Interrogating a Protein Compound for Possible Therapeutic Approaches to ALS and FTD

UNDER THE MICROSCOPE: Ludo Van Den Bosch on Returning to Work, Exploring Therapeutic Strategies to Battle ALS & FTD

UNDER THE MICROSCOPE: Ludo Van Den Bosch on Returning to Work, Exploring Therapeutic Strategies to Battle ALS & FTD

Searching for Information, a Media Resource Offers Credible, Compassionate News and Relatable Stories to the ALS Community

Searching for Information, a Media Resource Offers Credible, Compassionate News and Relatable Stories to the ALS Community

Under the Microscope: Fen-Biao Gao ofUMass Medical School Explains His Now-Funded Project Targeting Biomarkers and Disease Modifiers for ALS and FTD

Under the Microscope: Fen-Biao Gao ofUMass Medical School Explains His Now-Funded Project Targeting Biomarkers and Disease Modifiers for ALS and FTD

Building a Safer Future: How Matt’s Place Foundation is Helping ALS Patients With Home Accessibility

Building a Safer Future: How Matt’s Place Foundation is Helping ALS Patients With Home Accessibility

Target ALS and AFTD Announce $5MM in Grants for Research Targeting Treatments and Biomarkers

Target ALS and AFTD Announce $5MM in Grants for Research Targeting Treatments and Biomarkers

Target ALS and The ALS Association Announce New TDP-43-Focused Biomarker Initiative

Target ALS and The ALS Association Announce New TDP-43-Focused Biomarker Initiative

Target ALS Annual Meeting Canceled Due to the Spread of COVID-19

Target ALS Annual Meeting Canceled Due to the Spread of COVID-19

Target ALS Expands Stem Cell Core to Include Innovative New Reporter Lines

Target ALS Expands Stem Cell Core to Include Innovative New Reporter Lines

What’s Next for Target ALS? A Preview of Our Work in 2020

What’s Next for Target ALS? A Preview of Our Work in 2020

Thanks to Your Support: $35 Million Raised in 2019

Thanks to Your Support: $35 Million Raised in 2019

Target ALS Innovation Ecosystem Impact & Upcoming Initiatives

ALS/FTD Response Signals Resounding Desire for Collaboration

ALS/FTD Response Signals Resounding Desire for Collaboration

A Cancer Drug for ALS? Organization Forges Promising ALS Treatment, an Innovative Approach to Incubate Novel Therapeutics

A Cancer Drug for ALS? Organization Forges Promising ALS Treatment, an Innovative Approach to Incubate Novel Therapeutics

NEWS: Target ALS-Funded Research Shows Promise in Slowing ALS Disease Progression Scientists Discover Method to Decrease Neuroinflammation and Extend Life Expectancy

NEWS: Target ALS-Funded Research Shows Promise in Slowing ALS Disease Progression Scientists Discover Method to Decrease Neuroinflammation and Extend Life Expectancy

150 Years Later, Still No Effective Treatment for ALS. New Research Model Offers Hope

150 Years Later, Still No Effective Treatment for ALS. New Research Model Offers Hope

NEWS: Target ALS Biosample Recipients Identify Three Distinct Subtypes of ALS

NEWS: Target ALS Biosample Recipients Identify Three Distinct Subtypes of ALS

Target ALS & AFTD Announce Groundbreaking Partnership to Spur Drug and Biomarker Development for ALS and FTD

Target ALS & AFTD Announce Groundbreaking Partnership to Spur Drug and Biomarker Development for ALS and FTD

The Boston Globe Features Target ALS Founder, Dan Doctoroff

The Boston Globe Features Target ALS Founder, Dan Doctoroff

Target ALS Awards Six Innovative Research Teams with Additional Target Discovery Funds

Target ALS Awards Six Innovative Research Teams with Additional Target Discovery Funds

American Academy of Neurology and Target ALS Partner to Accelerate ALS Research

American Academy of Neurology and Target ALS Partner to Accelerate ALS Research

Case Study: Collaboration Accelerates Potential ALS Treatment

Case Study: Collaboration Accelerates Potential ALS Treatment

Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

Target ALS Foundation Makes Human Stem Cell Lines Accessible to Researchers

Target ALS Foundation Makes Human Stem Cell Lines Accessible to Researchers

Target ALS Providing Critical Tool to Study C9ORF72 Biology

Target ALS Providing Critical Tool to Study C9ORF72 Biology

Case Study: Biomarkers Offer Optimism for People with ALS

Case Study: Biomarkers Offer Optimism for People with ALS

New Biomarker Study with Academic, Industry and Philanthropic Partners

New Biomarker Study with Academic, Industry and Philanthropic Partners

Target ALS expands core facilities access to MDA development grant awardees

Target ALS expands core facilities access to MDA development grant awardees

Target ALS Foundation Selects RUCDR Infinite Biologics

Target ALS Foundation Selects RUCDR Infinite Biologics

Partnership to Uncover Connection Between Ancient Retroviruses and ALS

Partnership to Uncover Connection Between Ancient Retroviruses and ALS

Biogen and Target ALS Foundation Announce $20 Million Funding Challenge

Biogen and Target ALS Foundation Announce $20 Million Funding Challenge

The New York Times Features Daniel L. Doctoroff, Target ALS Founder

The New York Times Features Daniel L. Doctoroff, Target ALS Founder